Phase 1 trial suggests benefit of psilocybin in OCD treatment
The Brown University Psychopharmacology Update · 2026-08 · 37 (8) · 3-4
DOI: 10.1002/pu.31474 ↗At a glance
Journal article in The Brown University Psychopharmacology Update, published online on 2026-06-28.
Abstract (original language)
A Phase 1 trial comprising 15 patients has found that repeated high‐dose administration of psilocybin was more effective than low‐dose psilocybin or placebo in reducing symptoms of obsessive‐compulsive disorder (OCD). Psilocybin was generally well‐tolerated, with no reports of serious adverse events.
Cite
APA
(2026). Phase 1 trial suggests benefit of psilocybin in OCD treatment. The Brown University Psychopharmacology Update, 37(8), 3-4. https://doi.org/10.1002/pu.31474
Vancouver
Phase 1 trial suggests benefit of psilocybin in OCD treatment. The Brown University Psychopharmacology Update. 2026;37(8):3-4. doi:10.1002/pu.31474
BibTeX
@article{euvimed2026,
title = {Phase 1 trial suggests benefit of psilocybin in OCD treatment},
journal = {The Brown University Psychopharmacology Update},
year = {2026},
volume = {37},
number = {8},
pages = {3--4},
doi = {10.1002/pu.31474}
}
EUVIMED